303 related articles for article (PubMed ID: 12526951)
1. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
[TBL] [Abstract][Full Text] [Related]
2. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
[TBL] [Abstract][Full Text] [Related]
3. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
4. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
[TBL] [Abstract][Full Text] [Related]
5. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
8. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ
Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
13. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
[TBL] [Abstract][Full Text] [Related]
14. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
Joh JW; Lee HH; Park JW; Lee DH; Yoo BC; Lee KW; Kim SJ
Transplant Proc; 2005 Mar; 37(2):1235-7. PubMed ID: 15848680
[TBL] [Abstract][Full Text] [Related]
15. Viral features of lamivudine resistant hepatitis B genotypes A and D.
Zöllner B; Petersen J; Puchhammer-Stöckl E; Kletzmayr J; Sterneck M; Fischer L; Schröter M; Laufs R; Feucht HH
Hepatology; 2004 Jan; 39(1):42-50. PubMed ID: 14752821
[TBL] [Abstract][Full Text] [Related]
16. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
17. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
18. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
Lee CH; Kim SO; Byun KS; Moon MS; Kim EO; Yeon JE; Yoo W; Hong SP
Gastroenterology; 2006 Apr; 130(4):1144-52. PubMed ID: 16618409
[TBL] [Abstract][Full Text] [Related]
19. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
Yang DH; Liang WF; Xie YJ; Zhao NF; Fan J
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
[TBL] [Abstract][Full Text] [Related]
20. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
Selabe SG; Song E; Burnett RJ; Mphahlele MJ
J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
